Teladoc (NYSE:TDOC) was upgraded by stock analysts at TheStreet from a “d+” rating to a “c” rating in a note issued to investors on Wednesday, August 22nd.

TDOC has been the topic of several other reports. Canaccord Genuity increased their price target on shares of Teladoc from $47.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, June 5th. Craig Hallum upgraded shares of Teladoc from a “hold” rating to a “buy” rating in a research report on Tuesday, June 5th. Robert W. Baird increased their price target on Teladoc from $50.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday, July 25th. Chardan Capital increased their price target on Teladoc from $73.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Finally, MED increased their price target on Teladoc to $56.00 and gave the stock a “hold” rating in a report on Thursday, June 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Teladoc has an average rating of “Buy” and an average target price of $65.10.

NYSE TDOC traded down $0.45 during trading hours on Wednesday, reaching $77.30. The company had a trading volume of 947,063 shares, compared to its average volume of 1,118,675. The stock has a market capitalization of $5.35 billion, a P/E ratio of -46.85 and a beta of 0.58. Teladoc has a 1-year low of $27.30 and a 1-year high of $79.64. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.14 and a quick ratio of 3.14.

Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.01. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The business had revenue of $94.60 million for the quarter, compared to analysts’ expectations of $91.56 million. During the same quarter in the prior year, the company earned ($0.28) earnings per share. The business’s quarterly revenue was up 112.1% on a year-over-year basis. analysts anticipate that Teladoc will post -1.51 EPS for the current year.

In related news, SVP Andrew Turitz sold 13,821 shares of the business’s stock in a transaction that occurred on Tuesday, July 3rd. The stock was sold at an average price of $59.43, for a total transaction of $821,382.03. Following the transaction, the senior vice president now directly owns 9,378 shares of the company’s stock, valued at approximately $557,334.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Peter A. Mcclennen sold 91,072 shares of the business’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $65.84, for a total value of $5,996,180.48. Following the transaction, the president now directly owns 61,660 shares in the company, valued at $4,059,694.40. The disclosure for this sale can be found here. Insiders sold a total of 242,497 shares of company stock valued at $16,108,269 in the last 90 days. 3.95% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in TDOC. Global Thematic Partners LLC acquired a new position in Teladoc during the 1st quarter worth approximately $51,465,000. Bank of America Corp DE raised its position in shares of Teladoc by 82.8% in the 2nd quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after purchasing an additional 853,076 shares in the last quarter. Summit Partners L P acquired a new position in shares of Teladoc in the 2nd quarter valued at approximately $37,772,000. Westwood Management Corp IL raised its position in shares of Teladoc by 1,342.6% in the 2nd quarter. Westwood Management Corp IL now owns 585,700 shares of the health services provider’s stock valued at $34,000,000 after purchasing an additional 545,100 shares in the last quarter. Finally, Bellevue Group AG raised its position in shares of Teladoc by 997.2% in the 1st quarter. Bellevue Group AG now owns 515,694 shares of the health services provider’s stock valued at $20,782,000 after purchasing an additional 468,694 shares in the last quarter.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.